CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.

[1]  H. Rosenberg,et al.  Report of the Second Workshop on Age Adjustment. , 1998, Vital and health statistics. Ser. 4, Documents and committee reports.

[2]  Scott L. Pomeroy,et al.  Medulloblastomics: the end of the beginning , 2012, Nature Reviews Cancer.

[3]  D. Brachman,et al.  Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131 , 2015, Journal of Neuro-Oncology.

[4]  M. Fay.  Estimating age conditional probability of developing disease from surveillance data , 2004, Population health metrics.

[5]  Ram C Tiwari,et al.  Efficient interval estimation for age-adjusted cancer rates , 2006, Statistical methods in medical research.

[6]  A. Jemal,et al.  Annual Report to the Nation on the status of cancer, 1975‐2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer , 2014, Cancer.

[7]  S. Qi,et al.  Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms , 2014, Oncology letters.

[8]  H. Grönberg,et al.  Familial aggregation of astrocytoma in northern Sweden: An epidemiological cohort study , 1999, International journal of cancer.

[9]  Winand N M Dinjens,et al.  Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Mariotto,et al.  Evaluation of North American Association of Central Cancer Registries' (NAACCR) data for use in population-based cancer survival studies. , 2014, Journal of the National Cancer Institute. Monographs.

[11]  H M Rosenberg,et al.  Age standardization of death rates: implementation of the year 2000 standard. , 1998, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[12]  Eva Steliarova-Foucher,et al.  International Classification of Childhood Cancer, third edition , 2005, Cancer.

[13]  H. Grönberg,et al.  Familial brain tumours—genetics or environment? A nationwide cohort study of cancer risk in spouses and first‐degree relatives of brain tumour patients , 2003, International journal of cancer.

[14]  Steven J. M. Jones,et al.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.

[15]  R Miike,et al.  Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. , 1997, American journal of epidemiology.

[16]  Mark R Gilbert,et al.  Chemoradiotherapy in malignant glioma: standard of care and future directions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[18]  E. Feuer,et al.  Permutation tests for joinpoint regression with applications to cancer rates. , 2000, Statistics in medicine.

[19]  G. Barnett,et al.  Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States. , 2015, Neuro-oncology.

[20]  J. Barnholtz-Sloan,et al.  Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010 , 2016, Neuro-oncology.

[21]  M. Turner.  Epidemiology: allergy history, IgE, and cancer , 2012, Cancer Immunology, Immunotherapy.

[22]  J. Barnholtz-Sloan,et al.  The epidemiology of glioma in adults: a "state of the science" review. , 2014, Neuro-oncology.

[23]  D. Brat,et al.  Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004–2011 , 2015, Journal of Neuro-Oncology.

[24]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[25]  Amar Gajjar,et al.  The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma , 2014, Nature Genetics.

[26]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[27]  Chris Jones,et al.  Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma , 2014, Nature Reviews Cancer.

[28]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[29]  Jill S. Barnholtz-Sloan,et al.  Childhood Brain Tumor Epidemiology: A Brain Tumor Epidemiology Consortium Review , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[30]  G. Barger,et al.  Discrepancies in diagnoses of neuroepithelial neoplasms , 2000, Cancer.

[31]  Douglas Midthune,et al.  Modeling Reporting Delays and Reporting Corrections in Cancer Registry Data , 2005 .

[32]  L. Macconaill,et al.  Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma , 2012, Pediatric blood & cancer.

[33]  Jill S Barnholtz-Sloan,et al.  Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. , 2015, Neuro-oncology.

[34]  Kevin B. Zhang,et al.  Coding completeness and quality of relative survival-related variables in the National Program of Cancer Registries Cancer Surveillance System, 1995-2008. , 2014, Journal of registry management.

[35]  H. Heinzl,et al.  The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry , 2009, Journal of Neuro-Oncology.

[36]  Roland Eils,et al.  The whole-genome landscape of medulloblastoma subtypes , 2017, Nature.

[37]  R. Henriksson,et al.  Brain tumors in Sweden: Data from a population-based registry 1999–2012 , 2015, Acta oncologica.

[38]  E. Shaw,et al.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  C. Kruchko,et al.  Are Benign and Borderline Brain Tumors Underreported? , 2016, Journal of registry management.

[40]  J. Barnholtz-Sloan,et al.  American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. , 2016, Neuro-oncology.

[41]  J. Herman,et al.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas , 2012, Acta Neuropathologica.

[43]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[44]  Kimberly J. Johnson,et al.  Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. , 2012, Neuro-oncology.

[45]  Arun K. Ramani,et al.  Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics , 2016, Acta Neuropathologica Communications.

[46]  Jill S Barnholtz-Sloan,et al.  Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010 , 2014, Cancer.

[47]  J. Barnholtz-Sloan,et al.  Survivorship in adults with malignant brain and other central nervous system tumor from 2000-2014. , 2018, Neuro-oncology.

[48]  D. Ziegler,et al.  Genomic Insights into Diffuse Intrinsic Pontine Glioma , 2017, Front. Oncol..

[49]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[50]  E. Feuer,et al.  Impact of reporting delay and reporting error on cancer incidence rates and trends. , 2002, Journal of the National Cancer Institute.

[51]  G. Reifenberger,et al.  Advances in the molecular genetics of gliomas — implications for classification and therapy , 2017, Nature Reviews Clinical Oncology.

[52]  Eric J Feuer,et al.  Age‐conditional probabilities of developing cancer , 2003, Statistics in medicine.

[53]  P. Northcott,et al.  Molecular subgroups of medulloblastoma , 2012, Expert review of neurotherapeutics.

[54]  J. Bruner,et al.  Consensus Conference on Brain Tumor Definition for registration. November 10, 2000. , 2002, Neuro-oncology.

[55]  P. Black,et al.  Cancer in first-degree relatives and risk of glioma in adults. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[56]  J. Barnholtz-Sloan,et al.  Years of life lived with disease and years of potential life lost in children who die of cancer in the United States, 2009 , 2015, Cancer medicine.

[57]  D. Brat,et al.  Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004–2012, varying) , 2016, Journal of Neuro-Oncology.

[58]  A. Jemal,et al.  Predicting US‐ and state‐level cancer counts for the current calendar year , 2012, Cancer.

[59]  Joseph Wiemels,et al.  Epidemiology and etiology of meningioma , 2010, Journal of Neuro-Oncology.

[60]  A. Kaye,et al.  Frontal glioblastoma multiforme may be biologically distinct from non-frontal and multilobar tumors , 2016, Journal of Clinical Neuroscience.

[61]  K. Aldape,et al.  Aggregation of Cancer in First-Degree Relatives of Patients with Glioma , 2007, Cancer Epidemiology Biomarkers & Prevention.

[62]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[63]  J. Barnholtz-Sloan,et al.  The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone. , 2018, Neuro-oncology.

[64]  B. Scheithauer,et al.  The New WHO Classification of Brain Tumours , 1993, Brain pathology.

[65]  C. Kruchko,et al.  The impact of the Benign Brain Tumor Cancer Registries Amendment Act (Public Law 107-260) on non-malignant brain and central nervous system tumor incidence trends. , 2013, Journal of registry management.

[66]  Martin J. Bent,et al.  Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective , 2010, Acta Neuropathologica.

[67]  M. J. van den Bent,et al.  MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951 , 2013, Clinical Cancer Research.

[68]  David T. W. Jones,et al.  Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma , 2014, Acta Neuropathologica.

[69]  Kun Mu,et al.  Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma , 2017, Cancer cell.

[70]  Rebecca L. Siegel Mph,et al.  Cancer statistics, 2016 , 2016 .